David P. Perry

Insider Reports History

Reporting-owner location: Palo Alto, CA
Latest reporting-owner signature: /s/ Shoaib Ghias, Attorney-in-Fact for David P. Perry
Source: Latest parsed Forms 3/4/5 signature
Transaction source note: Rows are grouped by transaction date from the original SEC filing. Open the aggregated insider activity page to review issuer-level activity across dates.

Reported holdings for David P. Perry

Form 4 holding Executive Chairman, Director, 10%+ Owner

Better Therapeutics, Inc.

Security class: Common Stock
Shares / value: 13,030,393
Estimated value: $2,482,290
Report date: 09 Feb 2024
Price: $0.1905
Ownership: By Perry Trust

Form 4 holding Executive Chairman, Director, 10%+ Owner

Better Therapeutics, Inc.

Security class: Common Stock
Shares / value: 3,636,364
Estimated value: $692,727
Report date: 09 Feb 2024
Price: $0.1905
Ownership: By Maule-Ffinch Trust

Form 4 holding Executive Chairman, Director, 10%+ Owner

Better Therapeutics, Inc.

Security class: Common Stock
Shares / value: 2,416,634
Estimated value: $460,369
Report date: 09 Feb 2024
Price: $0.1905
Ownership: Direct

Form 4 holding Executive Chairman, Director, 10%+ Owner

Better Therapeutics, Inc.

Security class: Common Stock
Shares / value: 293,150
Estimated value: $55,845
Report date: 09 Feb 2024
Price: $0.1905
Ownership: By spouse

Form 4 holding Executive Chairman, Director, 10%+ Owner

Better Therapeutics, Inc.

Security class: Common Stock
Shares / value: 21,336
Estimated value: $4,065
Report date: 09 Feb 2024
Price: $0.1905
Ownership: By Pensus Limited Trust

Form 4 holding Director

Evelo Biosciences, Inc.

Security class: Stock Option (Right to Buy)
Shares / value: 1,810
Estimated value
Report date: 09 Jun 2021
Price
Ownership: Direct
Underlying class: Common Stock
Underlying amount

Insider Reports Filed by David P. Perry

4

Better Therapeutics, Inc.

Report period: 09 Feb 2024
Transactions: 1
Transaction value: +$160,000
Accepted by SEC: 13 Feb 2024, 21:50
Role: Executive Chairman, Director, 10%+ Owner
Next action: Open filing details

4

Better Therapeutics, Inc.

Report period: 09 Jan 2024
Transactions: 1
Transaction value: +$250,000
Accepted by SEC: 10 Jan 2024, 16:19
Role: Executive Chairman, Director, 10%+ Owner
Next action: Open filing details

4

Better Therapeutics, Inc.

Report period: 18 Dec 2023
Transactions: 1
Transaction value: $0
Accepted by SEC: 20 Dec 2023, 17:24
Role: Executive Chairman, Director, 10%+ Owner
Next action: Open filing details

4

Better Therapeutics, Inc.

Report period: 27 Jul 2023
Transactions: 1
Transaction value: +$900,000
Accepted by SEC: 31 Jul 2023, 07:59
Role: Executive Chairman, Director, 10%+ Owner
Next action: Open filing details

4

Better Therapeutics, Inc.

Report period: 07 Jun 2023
Transactions: 1
Transaction value: $0
Accepted by SEC: 09 Jun 2023, 18:54
Role: Executive Chairman, Director, 10%+ Owner
Next action: Open filing details

4

Better Therapeutics, Inc.

Report period: 10 Apr 2023
Transactions: 2
Transaction value: +$4,100,000
Accepted by SEC: 12 Apr 2023, 21:44
Role: Executive Chairman of the Board of Directors, Director, 10%+ Owner
Next action: Open filing details

4

Better Therapeutics, Inc.

Report period: 15 Sep 2022
Transactions: 2
Transaction value: +$102,598
Accepted by SEC: 19 Sep 2022, 06:06
Role: Executive Chairman of the Board of Directors, Director, 10%+ Owner
Next action: Open filing details

4

Better Therapeutics, Inc.

Report period: 09 Jun 2022
Transactions: 1
Transaction value: $0
Accepted by SEC: 10 Jun 2022, 16:39
Role: Executive Chairman of the Board of Directors, Director, 10%+ Owner
Next action: Open filing details

3

Better Therapeutics, Inc.

Report period: 28 Oct 2021
Transactions: 0
Transaction value: $0
Accepted by SEC: 01 Nov 2021, 20:28
Role: Executive Chairman of the Board of Directors Exhibit 24 - Power of Attorney, Director, 10%+ Owner
Next action: Open filing details

4

Evelo Biosciences, Inc.

Report period: 08 Jun 2021
Transactions: 2
Transaction value: $0
Accepted by SEC: 11 Jun 2021, 16:06
Role: Director
Next action: Open filing details

4

Better Therapeutics, Inc.

Report period: 30 Apr 2021
Transactions: 13
Transaction value: +$3,512,432
Accepted by SEC: 01 Nov 2021, 20:55
Role: Executive Chairman of the Board of Directors, Director, 10%+ Owner
Next action: Open filing details

We use cookies and similar technologies to provide certain features, enhance the user experience and, if you allow them, measure engagement and deliver advertising. Analytics and marketing storage stay off until you grant consent. By clicking on "Agree and continue", you declare your consent to the use of the selected optional cookies. to update or revoke optional consent for future visits. For more information, see our Privacy Policy .